Figure 3.
Flow cytometric evaluation of PBMCs collected immediately before blinatumomab treatment on day 42 after auto-HCT. Flow cytometry was performed on cryopreserved PBMCs collected on day 42 (before blinatumomab) after auto-HCT. Samples from patients who remained in remission (CR; n = 4) were compared with those from patients with relapsed disease (PD; n = 10) and peripheral blood samples collected from 5 healthy untreated donor controls (HDs). (A) Percentage of CD19+CD20+ B cells, CD3+CD56−CD8+ T cells (CD8 T), and CD3+CD56−CD4+ T cells (CD4 T) within the total CD45+ hematopoietic cells. (B) The ratio of CD8 to CD4 T cells within the CD3+CD56− T-cell subset. (C-D) Relative percentages of naïve (CD45RA+CD197+), central memory (CM; CD45RA−CD197+), EM (CD45RA−CD197-), and EMRA (CD45RA+CD197−) CD4 (C) or CD8 (D) T-cell subsets. (E) Percentage of CD4 T helper subsets within the CD3+CD56−CD4+CD45RA− T memory population or regulatory T-cell (Treg; CD3+CD56−CD4+FoxP3+CD25+) subsets. Various chemokine receptors were used to distinguish Th-1 (CD185−CD196−CCR10−CD183+), Th-2 (CD185−CD196−CCR10−CD183−), Th-9 (CD185−CD194−CD196+), Th-17 (CD185−CD196+CCR10−CD183−CD194+), Th-22 (CD185−CD196+CCR10+CD183−CD194+), T follicular helper cells (T-fh; CD185+CCR10−), and T GM-CSF–secreting (Th-GMCSF; CD185−CD196−CCR10+CD183−) cells. (F-G) The percentage of CD4 (F) or CD8 (G) T cells expressing antigens that are altered during T-cell activation, proliferation, exhaustion, and trafficking. P values were calculated using a 2-way analysis of variance for repeated measurement data as described in “Methods.” ∗P < .05; ∗∗P < .001; ∗∗∗P < .0001; ∗∗∗∗P < .00001. EMRA, effector memory re-expressing CD45RA; Th-1, T helper type 1 cell.

Flow cytometric evaluation of PBMCs collected immediately before blinatumomab treatment on day 42 after auto-HCT. Flow cytometry was performed on cryopreserved PBMCs collected on day 42 (before blinatumomab) after auto-HCT. Samples from patients who remained in remission (CR; n = 4) were compared with those from patients with relapsed disease (PD; n = 10) and peripheral blood samples collected from 5 healthy untreated donor controls (HDs). (A) Percentage of CD19+CD20+ B cells, CD3+CD56−CD8+ T cells (CD8 T), and CD3+CD56−CD4+ T cells (CD4 T) within the total CD45+ hematopoietic cells. (B) The ratio of CD8 to CD4 T cells within the CD3+CD56− T-cell subset. (C-D) Relative percentages of naïve (CD45RA+CD197+), central memory (CM; CD45RA−CD197+), EM (CD45RA−CD197-), and EMRA (CD45RA+CD197−) CD4 (C) or CD8 (D) T-cell subsets. (E) Percentage of CD4 T helper subsets within the CD3+CD56−CD4+CD45RA− T memory population or regulatory T-cell (Treg; CD3+CD56−CD4+FoxP3+CD25+) subsets. Various chemokine receptors were used to distinguish Th-1 (CD185−CD196−CCR10−CD183+), Th-2 (CD185−CD196−CCR10−CD183−), Th-9 (CD185−CD194−CD196+), Th-17 (CD185−CD196+CCR10−CD183−CD194+), Th-22 (CD185−CD196+CCR10+CD183−CD194+), T follicular helper cells (T-fh; CD185+CCR10−), and T GM-CSF–secreting (Th-GMCSF; CD185−CD196−CCR10+CD183−) cells. (F-G) The percentage of CD4 (F) or CD8 (G) T cells expressing antigens that are altered during T-cell activation, proliferation, exhaustion, and trafficking. P values were calculated using a 2-way analysis of variance for repeated measurement data as described in “Methods.” ∗P < .05; ∗∗P < .001; ∗∗∗P < .0001; ∗∗∗∗P < .00001. EMRA, effector memory re-expressing CD45RA; Th-1, T helper type 1 cell.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal